The Experts below are selected from a list of 7698 Experts worldwide ranked by ideXlab platform
Charles S. Cleeland - One of the best experts on this subject based on the ideXlab platform.
-
Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients
Journal of pain and symptom management, 2017Co-Authors: Hossein Majedi, Charles S. Cleeland, Tito R. Mendoza, S. Sharareh Dehghani, Saeed Soleyman-jahi, S. Ali Emami Meibodi, S. Mohammad Mireskandari, Marzieh Hajiaghababaei, Abbas TafakhoriAbstract:Abstract Context Chronic Pain needs to be evaluated with a standard instrument. The Brief Pain Inventory (BPI) is a Pain assessment tool that has been validated in many languages. Objectives The aim of the present study was to develop the Persian version of the Brief Pain Inventory (BPI-P) and also to evaluate the psychometric properties of the BPI-P in the Iranian population. Methods The BPI-P was translated from the original version of BPI using standard procedure. The Persian version of the BPI and 12-item Short-Form Health Survey (SF-12) were completed by 201 patients with chronic Pain who were referred to a tertiary Pain care clinic from 2013 to 2015. The performance status of the patients was evaluated by physicians using Eastern Cooperative Oncology Group performance test. Results Factor analysis of the BPI-P identified two scales: Pain intensity and Pain interference with life. These two factors explained 68.4% of the variance. Coefficient alpha values for BPI-P items ranging from 0.87 to 0.91 showed good internal consistency of the factors. The high intraclass correlation coefficients for the items of the questionnaire confirmed the test-retest reliability for the BPI-P. Patients with higher scores in Eastern Cooperative Oncology Group performance test reported higher levels of Pain intensity and Pain interference with life. Pain intensity in BPI-P correlated with physical functioning, bodily Pain, mental health, and vitality of the SF-12 questionnaire, whereas Pain interference was associated with general health, bodily Pain, mental health, vitality, and social functioning. Conclusion The present study demonstrated that the Persian version of the BPI could be a valid and reliable instrument for Pain assessment in Persian-speaking patients.
-
using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory bpi
Journal of Pain and Symptom Management, 2011Co-Authors: Tito R. Mendoza, Laura Sit, Mike Fruscione, Dawn Lavene, Mary Shaw, Thomas M. Atkinson, Barry Rosenfeld, Jennifer L Hay, Charles S. CleelandAbstract:Abstract Context The Brief Pain Inventory (BPI) is a frequently used instrument designed to assess the patient-reported outcome of Pain. The majority of factor analytic studies have found a two-factor (i.e., Pain intensity and Pain interference) structure for this instrument; however, because the BPI was developed with an a priori hypothesis of the relationship among its items, it follows that construct validity investigations should use confirmatory factor analysis (CFA). Objectives The purpose of this work was to establish the construct validity of the BPI using a CFA framework and demonstrate factorial invariance using a range of demographic variables. Methods A retrospective CFA was completed in a sample of individuals diagnosed with HIV/AIDS and cancer ( n =364; 63% male; age 21–92 years, M=51.80). A baseline one-factor model was compared against two-factor and three-factor models (i.e., Pain intensity, activity interference, and affective interference) that were developed based on the hypothetical design of the instrument. Results Fit indices for the three-factor model were statistically superior when compared with the one-factor model and marginally better when compared with the two-factor model. This three-factor structure was found to be invariant across disease, age, and ethnicity groups. Conclusion The results of this study provide evidence to support a three-factor representation of the BPI, and the originally hypothesized two-factor structure. Such findings will begin to provide clinical trialists, pharmaceutical sponsors, and regulators with confidence in the psychometric properties of this instrument when considering its inclusion in clinical research.
-
Confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).
Journal of Clinical Oncology, 2010Co-Authors: Thomas M. Atkinson, Charles S. Cleeland, Tito R. Mendoza, Laura Sit, Mike Fruscione, Dawn Lavene, Mary Shaw, William Breitbart, Barry Rosenfeld, E. M. BaschAbstract:e19505 Background: The Brief Pain Inventory (BPI) is a frequently used instrument designed to assess the patient-reported outcome of Pain. Prior exploratory factor analysis study results have suggested a two-factor (i.e., Pain intensity and Pain interference) structure for this instrument; however, since the BPI was developed with an a priori hypothesis of the relationship amongst its items, it follows that investigations of construct validity should utilize confirmatory factor analysis (CFA). The purpose of this work is to establish the construct validity of the BPI using a CFA framework and demonstrate factorial invariance using a range of demographic variables. Methods: A retrospective CFA was completed in a sample of individuals diagnosed with cancer and HIV/AIDS (N = 364; 63% Male; Age 21-92, M = 51.78) who had been administered the BPI during routine palliative care. A baseline one-factor model was compared against two-factor and three-factor models (i.e., Pain intensity, activity interference, and ...
-
Validation of Brief Pain Inventory to Brazilian patients with Pain
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010Co-Authors: Karine Azevedo São Leão Ferreira, Manoel Jacobsen Teixeira, Tito R. Mendonza, Charles S. CleelandAbstract:Purpose To validate the Brazilian version of the Brief Pain Inventory (BPI-B) scale and to determine the optimal cutpoints for mild, moderate, and severe Pain based on patients' rating of their worst Pain.
-
the Brief Pain Inventory and its Pain at its worst in the last 24 hours item clinical trial endpoint considerations
Pain Medicine, 2010Co-Authors: Thomas M. Atkinson, Charles S. Cleeland, Tito R. Mendoza, Laura Sit, Steven D Passik, Howard I Scher, Ethan BaschAbstract:Context. In 2006, the United States Food and Drug Administration (FDA) released a draft Guidance for Industry on the use of patient-reported outcomes (PRO) Measures in Medical Product Development to Support Labeling Claims. This draft guidance outlines psychometric aspects that should be considered when designing a PRO measure, including conceptual framework, content validity, construct validity, reliability, and the ability to detect clinically meaningful score changes. When finalized, it may provide a blueprint for evaluations of PRO measures that can be considered by sponsors and investigators involved in PRO research and drug registration trials. Objective. In this review we examine the short form of the Brief Pain Inventory (BPI) and particularly the “Pain at its worst in the last 24 hours” item in the context of the FDA draft guidance, to assess its utility in clinical trials that include Pain as a PRO endpoint. Results and Conclusions. After a systematic evaluation of the psychometric aspects of the BPI, we conclude that the BPI and its “Pain at its worst in the last 24 hours” item generically satisfy most key recommendations outlined in the draft guidance for assessing a Pain-reduction treatment effect. Nonetheless, when the BPI is being considered for assessment of Pain endpoints in a registration trial, sponsors and investigators should consult with the appropriate FDA division early during research design to discuss whether there is sufficient precedent to use the instrument in the population of interest or whether additional evaluations of measurement properties are advisable.
Tito R. Mendoza - One of the best experts on this subject based on the ideXlab platform.
-
Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients
Journal of pain and symptom management, 2017Co-Authors: Hossein Majedi, Charles S. Cleeland, Tito R. Mendoza, S. Sharareh Dehghani, Saeed Soleyman-jahi, S. Ali Emami Meibodi, S. Mohammad Mireskandari, Marzieh Hajiaghababaei, Abbas TafakhoriAbstract:Abstract Context Chronic Pain needs to be evaluated with a standard instrument. The Brief Pain Inventory (BPI) is a Pain assessment tool that has been validated in many languages. Objectives The aim of the present study was to develop the Persian version of the Brief Pain Inventory (BPI-P) and also to evaluate the psychometric properties of the BPI-P in the Iranian population. Methods The BPI-P was translated from the original version of BPI using standard procedure. The Persian version of the BPI and 12-item Short-Form Health Survey (SF-12) were completed by 201 patients with chronic Pain who were referred to a tertiary Pain care clinic from 2013 to 2015. The performance status of the patients was evaluated by physicians using Eastern Cooperative Oncology Group performance test. Results Factor analysis of the BPI-P identified two scales: Pain intensity and Pain interference with life. These two factors explained 68.4% of the variance. Coefficient alpha values for BPI-P items ranging from 0.87 to 0.91 showed good internal consistency of the factors. The high intraclass correlation coefficients for the items of the questionnaire confirmed the test-retest reliability for the BPI-P. Patients with higher scores in Eastern Cooperative Oncology Group performance test reported higher levels of Pain intensity and Pain interference with life. Pain intensity in BPI-P correlated with physical functioning, bodily Pain, mental health, and vitality of the SF-12 questionnaire, whereas Pain interference was associated with general health, bodily Pain, mental health, vitality, and social functioning. Conclusion The present study demonstrated that the Persian version of the BPI could be a valid and reliable instrument for Pain assessment in Persian-speaking patients.
-
Validity and reliability of a Turkish Brief Pain Inventory short form when used to evaluate musculoskeletal Pain.
Journal of back and musculoskeletal rehabilitation, 2017Co-Authors: Evrim Coskun Celik, Tito R. Mendoza, Ebru Yilmaz Yalcinkaya, Funda Atamaz, Metin Karatas, Kadriye Öneş, Tezgul Sezer, Imran Eren, Nurdan Paker, Ibrahima GningAbstract:Background The Brief Pain Inventory (BPI) is both a questionnaire and an outcome measure that is used widely in clinical trials to assess Pain associated with many conditions. The BPI Short Form has been extensively translated into foreign languages. The aim of this study was to assess the validity and reliability of a Turkish Brief Pain Inventory Short Form (BPI-TR) to evaluate musculoskeletal Pain. Methods In total, 297 patients with musculoskeletal Pain participated in the study. Demographic characteristics and Brief medical histories were recorded. Pain intensity was assessed using a visual analogue scale (VAS) and quality-of-life was assessed using the Short Form 36 (SF-36). Pain was evaluated using the BPI-TR in all patients. Internal consistency and test-retest analysis were used to assess reliability. The internal consistency of the scale items was assessed by calculating Cronbach's α value, which was expected to be > 0.7. The criterion validity of the BPI-TR was assessed by correlation with VAS scores. Results Pain intensity, Pain interference, and other components of the Turkish version were consistent with validity thereof. Cronbach's α was 0.84 for Pain intensity and 0.89 for Pain interference. The extent of BPI-TR and VAS correlation was statistically significant. Conclusions The BPI-TR may be used for assessment of musculoskeletal Pain.
-
using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory bpi
Journal of Pain and Symptom Management, 2011Co-Authors: Tito R. Mendoza, Laura Sit, Mike Fruscione, Dawn Lavene, Mary Shaw, Thomas M. Atkinson, Barry Rosenfeld, Jennifer L Hay, Charles S. CleelandAbstract:Abstract Context The Brief Pain Inventory (BPI) is a frequently used instrument designed to assess the patient-reported outcome of Pain. The majority of factor analytic studies have found a two-factor (i.e., Pain intensity and Pain interference) structure for this instrument; however, because the BPI was developed with an a priori hypothesis of the relationship among its items, it follows that construct validity investigations should use confirmatory factor analysis (CFA). Objectives The purpose of this work was to establish the construct validity of the BPI using a CFA framework and demonstrate factorial invariance using a range of demographic variables. Methods A retrospective CFA was completed in a sample of individuals diagnosed with HIV/AIDS and cancer ( n =364; 63% male; age 21–92 years, M=51.80). A baseline one-factor model was compared against two-factor and three-factor models (i.e., Pain intensity, activity interference, and affective interference) that were developed based on the hypothetical design of the instrument. Results Fit indices for the three-factor model were statistically superior when compared with the one-factor model and marginally better when compared with the two-factor model. This three-factor structure was found to be invariant across disease, age, and ethnicity groups. Conclusion The results of this study provide evidence to support a three-factor representation of the BPI, and the originally hypothesized two-factor structure. Such findings will begin to provide clinical trialists, pharmaceutical sponsors, and regulators with confidence in the psychometric properties of this instrument when considering its inclusion in clinical research.
-
Confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI).
Journal of Clinical Oncology, 2010Co-Authors: Thomas M. Atkinson, Charles S. Cleeland, Tito R. Mendoza, Laura Sit, Mike Fruscione, Dawn Lavene, Mary Shaw, William Breitbart, Barry Rosenfeld, E. M. BaschAbstract:e19505 Background: The Brief Pain Inventory (BPI) is a frequently used instrument designed to assess the patient-reported outcome of Pain. Prior exploratory factor analysis study results have suggested a two-factor (i.e., Pain intensity and Pain interference) structure for this instrument; however, since the BPI was developed with an a priori hypothesis of the relationship amongst its items, it follows that investigations of construct validity should utilize confirmatory factor analysis (CFA). The purpose of this work is to establish the construct validity of the BPI using a CFA framework and demonstrate factorial invariance using a range of demographic variables. Methods: A retrospective CFA was completed in a sample of individuals diagnosed with cancer and HIV/AIDS (N = 364; 63% Male; Age 21-92, M = 51.78) who had been administered the BPI during routine palliative care. A baseline one-factor model was compared against two-factor and three-factor models (i.e., Pain intensity, activity interference, and ...
-
the Brief Pain Inventory and its Pain at its worst in the last 24 hours item clinical trial endpoint considerations
Pain Medicine, 2010Co-Authors: Thomas M. Atkinson, Charles S. Cleeland, Tito R. Mendoza, Laura Sit, Steven D Passik, Howard I Scher, Ethan BaschAbstract:Context. In 2006, the United States Food and Drug Administration (FDA) released a draft Guidance for Industry on the use of patient-reported outcomes (PRO) Measures in Medical Product Development to Support Labeling Claims. This draft guidance outlines psychometric aspects that should be considered when designing a PRO measure, including conceptual framework, content validity, construct validity, reliability, and the ability to detect clinically meaningful score changes. When finalized, it may provide a blueprint for evaluations of PRO measures that can be considered by sponsors and investigators involved in PRO research and drug registration trials. Objective. In this review we examine the short form of the Brief Pain Inventory (BPI) and particularly the “Pain at its worst in the last 24 hours” item in the context of the FDA draft guidance, to assess its utility in clinical trials that include Pain as a PRO endpoint. Results and Conclusions. After a systematic evaluation of the psychometric aspects of the BPI, we conclude that the BPI and its “Pain at its worst in the last 24 hours” item generically satisfy most key recommendations outlined in the draft guidance for assessing a Pain-reduction treatment effect. Nonetheless, when the BPI is being considered for assessment of Pain endpoints in a registration trial, sponsors and investigators should consult with the appropriate FDA division early during research design to discuss whether there is sufficient precedent to use the instrument in the population of interest or whether additional evaluations of measurement properties are advisable.
Dan J. Stein - One of the best experts on this subject based on the ideXlab platform.
-
Pain in amaxhosa women living with hiv aids translation and validation of the Brief Pain Inventory xhosa
Journal of Pain and Symptom Management, 2016Co-Authors: Romy Parker, Jennifer Jelsma, Dan J. SteinAbstract:Abstract Context Pain has been reported as the second most commonly reported symptom in people living with HIV/AIDS. In South Africa, there are more than five million people living with HIV/AIDS. Approximately, two million belong to the Xhosa cultural group. The prevalence of Pain in amaXhosa living with HIV/AIDS was unknown at the commencement of the study. A culturally appropriate, valid, and reliable instrument is required to measure Pain and its impact in this population. Objectives The objectives of this article are to document the process of translation of the Brief Pain Inventory (BPI) into the BPI-Xhosa and to present the results of the validity and reliability testing of the instrument. Methods A six-stage forward-backward translation process was followed using bilingual and bicultural translators to ensure decentering of the process. The translated BPI-Xhosa, a demographic questionnaire and the European Quality of Life-5 Dimensions Xhosa version (EQ-5D-Xhosa) health-related quality of life instrument were administered to 229 amaXhosa women living with HIV/AIDS in a resource-poor urban settlement in South Africa. Results A 74.24% (95% CI: 68.2–79.47) prevalence of Pain was recorded. The BPI-Xhosa had good concurrent validity when compared with the previously validated EQ-5D-Xhosa. Factor analysis confirmed that the BPI-Xhosa had a two-factor structure (Pain severity and Pain interference). The instrument had good internal reliability, with Cronbach alphas of 0.77 and 0.83 for the Pain severity and Pain interference subscales, respectively. Conclusion The BPI-Xhosa is a valid instrument which can be used to measure Pain prevalence, severity, and interference in amaXhosa women living with HIV/AIDS.
-
Pain in amaXhosa Women Living With HIV/AIDS: Translation and Validation of the Brief Pain Inventory-Xhosa.
Journal of pain and symptom management, 2015Co-Authors: Romy Parker, Jennifer Jelsma, Dan J. SteinAbstract:Abstract Context Pain has been reported as the second most commonly reported symptom in people living with HIV/AIDS. In South Africa, there are more than five million people living with HIV/AIDS. Approximately, two million belong to the Xhosa cultural group. The prevalence of Pain in amaXhosa living with HIV/AIDS was unknown at the commencement of the study. A culturally appropriate, valid, and reliable instrument is required to measure Pain and its impact in this population. Objectives The objectives of this article are to document the process of translation of the Brief Pain Inventory (BPI) into the BPI-Xhosa and to present the results of the validity and reliability testing of the instrument. Methods A six-stage forward-backward translation process was followed using bilingual and bicultural translators to ensure decentering of the process. The translated BPI-Xhosa, a demographic questionnaire and the European Quality of Life-5 Dimensions Xhosa version (EQ-5D-Xhosa) health-related quality of life instrument were administered to 229 amaXhosa women living with HIV/AIDS in a resource-poor urban settlement in South Africa. Results A 74.24% (95% CI: 68.2–79.47) prevalence of Pain was recorded. The BPI-Xhosa had good concurrent validity when compared with the previously validated EQ-5D-Xhosa. Factor analysis confirmed that the BPI-Xhosa had a two-factor structure (Pain severity and Pain interference). The instrument had good internal reliability, with Cronbach alphas of 0.77 and 0.83 for the Pain severity and Pain interference subscales, respectively. Conclusion The BPI-Xhosa is a valid instrument which can be used to measure Pain prevalence, severity, and interference in amaXhosa women living with HIV/AIDS.
John T Farrar - One of the best experts on this subject based on the ideXlab platform.
-
Brief Pain Inventory–Facial minimum clinically important difference
Journal of neurosurgery, 2015Co-Authors: Sukhmeet Sandhu, John T Farrar, Casey H. Halpern, Venus Vakhshori, Keyvan Mirsaeedi-farahani, John Y. K. LeeAbstract:OBJECT Neurosurgeons are frequently the primary physicians measuring Pain relief in patients with trigeminal neuralgia (TN). Unfortunately, the measurement of Pain can be complex. The Brief Pain Inventory–Facial (BPI-Facial) is a reliable and validated multidimensional tool that consists of 18 questions. It measures 3 domains of Pain: 1) Pain intensity (worst and average Pain intensity), 2) interference with general activities of daily living (ADL), and 3) face-specific Pain interference. The objective of this paper is to determine the patient-reported minimum clinically important difference (MCID) using the BPI-Facial. METHODS The authors conducted a retrospective study of 234 patients with TN seen in a single neurosurgeon's office. Patients completed baseline and 1-month follow-up BPI-Facial questionnaires. The MCID was calculated using an anchor-based approach in which the defined anchor was the 7-point patient global impression of change (PGIC). Two statistical methods were employed: mean change score...
-
Brief Pain Inventory facial minimum clinically important difference
Journal of Neurosurgery, 2015Co-Authors: John T Farrar, Sukhmeet Sandhu, Casey H. Halpern, Venus Vakhshori, John Y. K. Lee, Keyvan MirsaeedifarahaniAbstract:OBJECT Neurosurgeons are frequently the primary physicians measuring Pain relief in patients with trigeminal neuralgia (TN). Unfortunately, the measurement of Pain can be complex. The Brief Pain Inventory–Facial (BPI-Facial) is a reliable and validated multidimensional tool that consists of 18 questions. It measures 3 domains of Pain: 1) Pain intensity (worst and average Pain intensity), 2) interference with general activities of daily living (ADL), and 3) face-specific Pain interference. The objective of this paper is to determine the patient-reported minimum clinically important difference (MCID) using the BPI-Facial. METHODS The authors conducted a retrospective study of 234 patients with TN seen in a single neurosurgeon's office. Patients completed baseline and 1-month follow-up BPI-Facial questionnaires. The MCID was calculated using an anchor-based approach in which the defined anchor was the 7-point patient global impression of change (PGIC). Two statistical methods were employed: mean change score...
-
comparison of force plate gait analysis and owner assessment of Pain using the canine Brief Pain Inventory in dogs with osteoarthritis
Journal of Veterinary Internal Medicine, 2013Co-Authors: Dorothy Cimino Brown, Raymond C Boston, John T FarrarAbstract:Background Lameness assessment using force plate gait analysis (FPGA) and owner assessment of chronic Pain using the Canine Brief Pain Inventory (CBPI) are valid and reliable methods of evaluating canine osteoarthritis. There are no studies comparing these 2 outcome measures. Objective Evaluate the relationship between CBPI Pain severity (PS) and interference (PI) scores with the vertical forces of FPGA as efficacy measures in canine osteoarthritis. Animals Sixty-eight client-owned dogs with osteoarthritis (50 hind limb and 18 forelimb). Methods Double-blind, randomized. Owners completed the CBPI, and dogs underwent FPGA on days 0 and 14. Dogs received carprofen or placebo on days 1 through 14. The change in PS and PI scores from day 0 to 14 were compared to the change in peak vertical force (PVF) and vertical impulse (VI). Results PS and PI scores significantly decreased in carprofen- compared with placebo-treated dogs (P = .002 and P = .03, respectively). PVF and VI significantly increased in carprofen- compared with placebo-treated dogs (P = .006 and P = .02, respectively). There was no correlation or concordance between the PS or PI score changes and change in PVF or VI. Conclusions and Clinical Importance In these dogs with hind limb or forelimb osteoarthritis, owner assessment of chronic Pain using the CBPI and assessment of lameness using FPGA detected significant improvement in dogs treated with carprofen. The lack of correlation or concordance between the change in owner scores and vertical forces suggests that owners were focused on behaviors other than lameness when making efficacy evaluations in their dogs.
-
Development of and psychometric testing for the Brief Pain Inventory-Facial in patients with facial Pain syndromes.
Journal of neurosurgery, 2010Co-Authors: John T Farrar, John Y. K. Lee, H. Isaac Chen, Christopher Urban, Anahita Hojat, Ephraim W. Church, Sharon X. XieAbstract:Object Outcomes in clinical trials on trigeminal Pain therapies require instruments with demonstrated reliability and validity. The authors evaluated the Brief Pain Inventory (BPI) in its existing form plus an additional 7 facial-specific items in patients referred to a single neurosurgeon for a diagnosis of facial Pain. The complete 18-item instrument is referred to as the BPI-Facial. Methods This study was a cross-sectional analysis of patients who completed the BPI-Facial. The diagnosis of classic versus atypical trigeminal neuralgia (TN) was made before analyzing the questionnaire results. A hypothesis-driven factor analysis was used to determine the principal components of the questionnaire. Item reliability and questionnaire validity were tested for these specific constructs. Results Data from 156 patients were analyzed, including 114 patients (73%) with classic and 42 (27%) with atypical TN. Using orthomax rotation factor analysis, 3 factors with an eigenvalue > 1.0 were identified—Pain intensity, ...
-
a novel approach to the use of animals in studies of Pain validation of the canine Brief Pain Inventory in canine bone cancer
Pain Medicine, 2009Co-Authors: Dorothy Cimino Brown, Raymond C Boston, James C. Coyne, John T FarrarAbstract:Objective. To validate the Canine Brief Pain Inventory (CBPI), which is based on the human Brief Pain Inventory (BPI), in a canine model of spontaneous bone cancer. Design and Participants. One hundred owners of dogs with bone cancer self-administered the CBPI on three occasions to test the reliability, validity, and responsiveness of the measure. Outcome Measures. Factor analysis, internal consistency, convergent validity, and an extreme group validation assessment were completed using the responses from the first administration of the CBPI. Test–retest reliability was evaluated using two administrations of the instrument, 1 week apart. Responsiveness was tested by comparing responses 3 weeks apart. Results. The “severity” and “interference” factors hypothesized based on the BPI were demonstrated in the CBPI in dogs with bone cancer. Internal consistency was high (Cronbach's alpha, 0.95 and 0.93), as was test–retest reliability (kappa, 0.73 and 0.65). Convergent validity was demonstrated with respect to quality of life (r = 0.49 and 0.63). Extreme group validation against normal dogs showed significantly higher factor scores (P < 0.001 for both). Conclusions. The CBPI reliably measures the same Pain constructs in the companion canine model of spontaneous bone cancer as the BPI does in people with bone cancer. This innovative approach to preclinical outcomes development, validating a preclinical outcome measure that directly corresponds to an outcome measure routinely used in clinical research, applied to a readily available animal model of spontaneous disease could transform the predictive ability of preclinical Pain studies.
Romy Parker - One of the best experts on this subject based on the ideXlab platform.
-
Pain in amaxhosa women living with hiv aids translation and validation of the Brief Pain Inventory xhosa
Journal of Pain and Symptom Management, 2016Co-Authors: Romy Parker, Jennifer Jelsma, Dan J. SteinAbstract:Abstract Context Pain has been reported as the second most commonly reported symptom in people living with HIV/AIDS. In South Africa, there are more than five million people living with HIV/AIDS. Approximately, two million belong to the Xhosa cultural group. The prevalence of Pain in amaXhosa living with HIV/AIDS was unknown at the commencement of the study. A culturally appropriate, valid, and reliable instrument is required to measure Pain and its impact in this population. Objectives The objectives of this article are to document the process of translation of the Brief Pain Inventory (BPI) into the BPI-Xhosa and to present the results of the validity and reliability testing of the instrument. Methods A six-stage forward-backward translation process was followed using bilingual and bicultural translators to ensure decentering of the process. The translated BPI-Xhosa, a demographic questionnaire and the European Quality of Life-5 Dimensions Xhosa version (EQ-5D-Xhosa) health-related quality of life instrument were administered to 229 amaXhosa women living with HIV/AIDS in a resource-poor urban settlement in South Africa. Results A 74.24% (95% CI: 68.2–79.47) prevalence of Pain was recorded. The BPI-Xhosa had good concurrent validity when compared with the previously validated EQ-5D-Xhosa. Factor analysis confirmed that the BPI-Xhosa had a two-factor structure (Pain severity and Pain interference). The instrument had good internal reliability, with Cronbach alphas of 0.77 and 0.83 for the Pain severity and Pain interference subscales, respectively. Conclusion The BPI-Xhosa is a valid instrument which can be used to measure Pain prevalence, severity, and interference in amaXhosa women living with HIV/AIDS.
-
Pain in amaXhosa Women Living With HIV/AIDS: Translation and Validation of the Brief Pain Inventory-Xhosa.
Journal of pain and symptom management, 2015Co-Authors: Romy Parker, Jennifer Jelsma, Dan J. SteinAbstract:Abstract Context Pain has been reported as the second most commonly reported symptom in people living with HIV/AIDS. In South Africa, there are more than five million people living with HIV/AIDS. Approximately, two million belong to the Xhosa cultural group. The prevalence of Pain in amaXhosa living with HIV/AIDS was unknown at the commencement of the study. A culturally appropriate, valid, and reliable instrument is required to measure Pain and its impact in this population. Objectives The objectives of this article are to document the process of translation of the Brief Pain Inventory (BPI) into the BPI-Xhosa and to present the results of the validity and reliability testing of the instrument. Methods A six-stage forward-backward translation process was followed using bilingual and bicultural translators to ensure decentering of the process. The translated BPI-Xhosa, a demographic questionnaire and the European Quality of Life-5 Dimensions Xhosa version (EQ-5D-Xhosa) health-related quality of life instrument were administered to 229 amaXhosa women living with HIV/AIDS in a resource-poor urban settlement in South Africa. Results A 74.24% (95% CI: 68.2–79.47) prevalence of Pain was recorded. The BPI-Xhosa had good concurrent validity when compared with the previously validated EQ-5D-Xhosa. Factor analysis confirmed that the BPI-Xhosa had a two-factor structure (Pain severity and Pain interference). The instrument had good internal reliability, with Cronbach alphas of 0.77 and 0.83 for the Pain severity and Pain interference subscales, respectively. Conclusion The BPI-Xhosa is a valid instrument which can be used to measure Pain prevalence, severity, and interference in amaXhosa women living with HIV/AIDS.